

Grifols sCD38

Cutting-edge technology
to overcome lab challenges

A soluble recombinant protein that blocks anti-CD38 antibodies, enabling subsequent screening, identification, and crossmatching. For the DG Gel system and conventional testing.



TYPING

GRIFOLS


Unlocking solutions for laboratory challenges

Complex testing is difficult, and adding monoclonal antibody therapies that interfere in IH testing only makes it harder.


In our world, blood transfusion serves as a life-saving measure, especially for multiple myeloma patients who require multiple transfusions.

You have many challenges, and your patient's treatment causing interference on serologic tests presents an additional hurdle to overcome.

With the introduction of daratumumab in the therapy of multiple myeloma, immunohematology became more complicated¹



Daratumumab in patient plasma interferes with IH testing



1. Oostendorp M, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. *Transfusion*. 2015; 55 (6 Pt 2):1555-62.

Create clearer clinical pictures¹ with less work burden

Grifols sCD38 is a soluble recombinant protein that blocks anti-CD38 antibodies, enabling subsequent screening, identification, and crossmatching using the DG Gel system.



Effortless precision

Our ready-to-use reagent simplifies the process with an easy and seamless experience. For the DG Gel system and conventional testing.



Assured reliability

Advanced technology supported by a standardized procedure and CE mark certification. Grifols sCD38 provides a reliable and efficient solution to ensure accurate and consistent results^{1,2}.




Timely transfusions


Rapid and efficient procedure that allows you to focus on getting the best matched blood to patients who need it most with no delays.



Grifols sCD38 blocks daratumumab², enabling subsequent IH testing



Sample pre-treatment: serum/plasma incubation with Grifols sCD38 at 37° for 15 min



CD38 is expressed in red blood cells

RESULTS

No agglutination due to daratumumab. This three-cell screening example shows a sample free of irregular antibodies.

- Easy procedure
- Quick TAT
- Ready-to-use reagents
- No need for a dedicated technician

1. G. Nounsi, et al. Neutralization of red cell antibodies using soluble proteins: application to anti-CD38 interferences. Medical Laboratory Observer. March 2021; 53(3):38-40.

2. Grifols sCD38-3.0-IFU-en

What users value about Grifols sCD38



“The preparation of dithiothreitol (DTT)-treated cells is lengthy and not immediate, whereas the analytical procedure for performing IAT with Grifols sCD38 is simple.”

Dr. Londero
Azienda Sanitaria Universitaria Friuli Centrale,
Udine, Italy

“What we like the most is the ease of use as well as the speed of the analysis. The turnaround time when shipping the samples to another laboratory takes an average of 24 hours and therefore may cause delay off the transfusion date.”

Dr. Pettinelli
Centre Hospitalier d'Angoulême, France

“This is an innovative method to neutralize anti-CD38 allowing us to successfully complete screening, identification and crossmatching.”

Dr. Legoff
Hospital Charles-Foix, France

“Grifols sCD38 is ready-to-use while the dithiothreitol (DTT) method requires prior preparation of the reagent.”

Dr. Paesano
Ospedale del Mare Napoli, Italy

PRODUCT INFORMATION

Product code	213686
Presentation	1 x 0.2 mL
Test volume	2-6 µL per test with DG Gel system
Storage	2-8°C



Antibodies against Duffy antigens may react weaker or negatively after Grifols sCD38 treatment.



IVD product bearing CE mark certification
Product registration and availability vary by country.
Ask your local Grifols representative for more information.

GRIFOLS

Manufactured by
Medion Grifols Diagnostics AG.
Bonnstrasse 9, CH-3186
Düdingen, Switzerland
Tel. +41 26 492 8501
www.grifols.com

Grifols International, S.A.
Parc Empresarial Can Sant Joan
Av. de la Generalitat, 152-158
08174 Sant Cugat del Vallès
Barcelona, Spain
Tel: +34 935 710 500